TY - JOUR
T1 - Post-pandemic maternity care planning for vaccination
T2 - A qualitative study of the experiences of women, partners, health care professionals, and policy makers in the United Kingdom
AU - Dasgupta, Tisha
AU - Easter, Abigail
AU - Boulding, Harriet
AU - Sutedja, Tania
AU - Khalil, Asma
AU - Mistry, Hiten
AU - Horgan, Gillian
AU - Van Citters, Aricca
AU - Nelson, Eugene C.
AU - von Dadelszen, Peter
AU - Duncan, Emma
AU - The RESILIENT Study Group
AU - Bick, Debra
AU - Dalrymple, Kathryn
AU - Fox-Rushby, Julia
AU - McGreevy, Alice
AU - Poston, Lucilla
AU - Seed, Paul Townsend
AU - Soley Bori, Marina
AU - Tydeman, Florence
AU - White, Sara
AU - Wolfe, Ingrid
AU - Wang, Yanzhong
AU - Silverio, Sergio A.
AU - Magee, Laura
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/9/11
Y1 - 2024/9/11
N2 - Maternal vaccination during pregnancy, in general and against COVID-19 infection, offers protection to both mother and baby, but uptake remains suboptimal. This study aimed to explore the perceptions regarding COVID-19 vaccination in pregnancy, particularly for marginalised populations and those living with social or medical complexity. A total of 96 semi-structured in-depth interviews were conducted with 40 women, 15 partners, 21 HCPs, and 20 policy makers, across all four nations of the United Kingdom (UK), discussing their lived experience of utilising, delivering, or developing policy for COVID-19 vaccination in pregnancy during the pandemic. Three themes were derived: (1) historical and social context, (2) communication of information and guidance, and (3) appraisal and action. Together these captured the participants’ legacy of mistrust in drugs during pregnancy; prior positive experiences; concerns about missing information, conflicting information, or false information about COVID-19 vaccines; and confusing guidance for pregnant women. The final theme describes the participants’ behaviour and actions undertaken consequent to their experiences and the available information. The findings suggest efforts to improve COVID-19 vaccination in pregnancy may be best focused on personalised communication of information. A trusting relationship and prior positive experiences with other vaccines, both in and outside of pregnancy, positively influenced perceptions of COVID-19 vaccination.
AB - Maternal vaccination during pregnancy, in general and against COVID-19 infection, offers protection to both mother and baby, but uptake remains suboptimal. This study aimed to explore the perceptions regarding COVID-19 vaccination in pregnancy, particularly for marginalised populations and those living with social or medical complexity. A total of 96 semi-structured in-depth interviews were conducted with 40 women, 15 partners, 21 HCPs, and 20 policy makers, across all four nations of the United Kingdom (UK), discussing their lived experience of utilising, delivering, or developing policy for COVID-19 vaccination in pregnancy during the pandemic. Three themes were derived: (1) historical and social context, (2) communication of information and guidance, and (3) appraisal and action. Together these captured the participants’ legacy of mistrust in drugs during pregnancy; prior positive experiences; concerns about missing information, conflicting information, or false information about COVID-19 vaccines; and confusing guidance for pregnant women. The final theme describes the participants’ behaviour and actions undertaken consequent to their experiences and the available information. The findings suggest efforts to improve COVID-19 vaccination in pregnancy may be best focused on personalised communication of information. A trusting relationship and prior positive experiences with other vaccines, both in and outside of pregnancy, positively influenced perceptions of COVID-19 vaccination.
KW - Maternity care
KW - COVID-19
KW - Vaccination
KW - Qualitative research
KW - Women
KW - Partners
KW - Healthcare professionals
KW - Policy Makers
KW - Women's Health
UR - http://www.scopus.com/inward/record.url?scp=85205228795&partnerID=8YFLogxK
U2 - 10.3390/vaccines12091042
DO - 10.3390/vaccines12091042
M3 - Article
SN - 2076-393X
VL - 12
SP - 1
EP - 16
JO - Vaccines
JF - Vaccines
IS - 9
M1 - 1042
ER -